Anti-inflammatory effects of perfluorocarbon compounds

Abstract

Perfluorocarbon compounds (PFCs) are of interest for the treatment of acute lung injury due to unique physicochemical properties such as high solubility for oxygen. Different respiratory treatment modalities (e.g., liquid ventilation or aerosolized PFCs) have been shown to decrease pulmonary inflammatory responses in addition to improving lung compliance in animal models of lung injury and in clinical trials. Specifically, PFC-based treatment modalities have been shown to reduce levels of cytokines, chemokines and other mediators of pulmonary inflammation in a PFC- and, to some extent, concentration-dependent manner. As a result, neutrophil adhesion, accumulation and activation are reduced in PFC-treated animals and in humans undergoing partial liquid ventilation. Although more fundamental studies of the underlying anti-inflammatory mechanisms are needed, respiratory treatment modalities involving PFCs hold great clinical promise.

Keywords::

• aerosol
• chemokine
• cytokine
• eicosanoid
• liquid ventilation
• neutrophil
• reactive oxygen species

Financial & competing interests disclosure

This publication was made possible by financial support from the National Institute of Environmental Health Sciences, NIH (ES012475). The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.